Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists.
Benzoxazines
/ pharmacology
Cannabinoid Receptor Agonists
/ pharmacology
Cannabinoids
/ pharmacology
Cyclic AMP
/ metabolism
Dronabinol
/ pharmacology
GTP-Binding Proteins
/ metabolism
HEK293 Cells
Humans
Indazoles
/ pharmacology
Indoles
/ pharmacology
Morpholines
/ pharmacology
Naphthalenes
/ pharmacology
Quinolines
/ pharmacology
Receptor, Cannabinoid, CB1
/ agonists
G protein
cannabinoid receptor
signaling
synthetic cannabinoid receptor agonist
toxicity
Journal
Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369
Informations de publication
Date de publication:
04 2020
04 2020
Historique:
received:
21
11
2019
revised:
23
01
2020
accepted:
27
01
2020
entrez:
27
2
2020
pubmed:
27
2
2020
medline:
7
4
2021
Statut:
ppublish
Résumé
Synthetic cannabinoid receptor agonists (SCRAs) are new psychoactive substances associated with acute intoxication and even death. However, the molecular mechanisms through which SCRAs may exert their toxic effects remain unclear-including the potential differential activation of G protein subtypes by cannabinoid receptor type 1 (CB1), a major target of SCRA. We measured CB1-mediated activation of Gα
Identifiants
pubmed: 32101383
doi: 10.1002/prp2.566
pmc: PMC7043210
doi:
Substances chimiques
1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester
0
5F-MDMB-PICA
0
Benzoxazines
0
Cannabinoid Receptor Agonists
0
Cannabinoids
0
Indazoles
0
Indoles
0
Morpholines
0
Naphthalenes
0
Quinolines
0
Receptor, Cannabinoid, CB1
0
(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone
5H31GI9502
Dronabinol
7J8897W37S
Cyclic AMP
E0399OZS9N
GTP-Binding Proteins
EC 3.6.1.-
1-pentyl-3-(1-naphthoyl)indole
G391998J57
AB-FUBINACA
I7PZF0KTFK
XLR-11
L2M8B977ZE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00566Informations de copyright
© 2020 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
Références
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19144-9
pubmed: 16365309
Proc Natl Acad Sci U S A. 2011 Sep 20;108(38):16086-91
pubmed: 21914848
Front Pharmacol. 2019 Apr 10;10:350
pubmed: 31024316
J Biol Chem. 2014 Sep 5;289(36):24845-62
pubmed: 25037227
Cell. 2019 Jan 24;176(3):448-458.e12
pubmed: 30639101
Arch Gen Psychiatry. 2001 Apr;58(4):322-8
pubmed: 11296091
J Pharmacol Exp Ther. 2011 Feb;336(2):296-302
pubmed: 21030484
Br J Pharmacol. 2013 Oct;170(4):893-907
pubmed: 23937487
Chem Rev. 2016 Jan 27;116(2):519-60
pubmed: 26741146
J Pharmacol Exp Ther. 2017 Apr;361(1):162-171
pubmed: 28087785
J Pharmacol Exp Ther. 2018 May;365(2):437-446
pubmed: 29549157
PeerJ. 2019 Sep 25;7:e7733
pubmed: 31579608
Neuropharmacology. 2015 Aug;95:68-82
pubmed: 25769232
Br J Pharmacol. 2013 Feb;168(3):554-75
pubmed: 22994528
Br J Pharmacol. 2010 Jun;160(3):747-61
pubmed: 20590577
Drug Test Anal. 2014 Jul-Aug;6(7-8):587-97
pubmed: 24995418
Mol Pharmacol. 2005 Jun;67(6):2016-24
pubmed: 15749995
Biochem Pharmacol. 2017 Mar 15;128:1-11
pubmed: 27890725
J Biol Chem. 2007 Apr 6;282(14):10576-84
pubmed: 17283075
J Pharmacol Exp Ther. 1998 Dec;287(3):884-8
pubmed: 9864268
J Biomol Screen. 2014 Feb;19(2):223-31
pubmed: 23989451
Br J Pharmacol. 2017 Dec;174 Suppl 1:S1-S16
pubmed: 29055037
ACS Chem Neurosci. 2016 Sep 21;7(9):1241-54
pubmed: 27421060
J Pharmacol Exp Ther. 2019 Feb;368(2):146-156
pubmed: 30420360
FEBS Lett. 1994 Aug 22;350(2-3):240-4
pubmed: 8070571
Forensic Sci Int. 2019 May;298:298-306
pubmed: 30925348
J Neurosci. 1997 Jul 15;17(14):5327-33
pubmed: 9204917
Clin Exp Pharmacol Physiol. 1999 Jul;26(7):493-9
pubmed: 10405772
Eur J Pharmacol. 2018 Mar 15;823:96-104
pubmed: 29408093
Forensic Toxicol. 2018;36(2):385-403
pubmed: 29963207
Eur J Pharmacol. 2001 Sep 28;428(1):51-7
pubmed: 11779037
Nat Commun. 2014 Sep 03;5:4767
pubmed: 25182477
Handb Exp Pharmacol. 2018;252:165-190
pubmed: 29980914
Front Pharmacol. 2019 May 29;10:595
pubmed: 31191320
Drug Test Anal. 2019 Aug;11(8):1264-1276
pubmed: 31108568
Br J Pharmacol. 2019 Dec;176(24):4653-4665
pubmed: 31412133
Expert Opin Ther Pat. 2009 Dec;19(12):1647-73
pubmed: 19939187
Forensic Sci Int. 2016 Mar;260:31-39
pubmed: 26795398
J Pharmacol Exp Ther. 2015 Sep;354(3):328-39
pubmed: 26105953
Drug Alcohol Depend. 2017 Oct 1;179:387-394
pubmed: 28846955
Toxicol Appl Pharmacol. 2018 Jan 1;338:1-8
pubmed: 29042214
Br J Pharmacol. 2017 Aug;174(15):2545-2562
pubmed: 28516479
ACS Chem Neurosci. 2019 Oct 16;10(10):4350-4360
pubmed: 31513380
J Mass Spectrom. 2009 May;44(5):832-7
pubmed: 19189348
Forensic Toxicol. 2016;34:329-343
pubmed: 27429655
N Engl J Med. 2017 Jan 19;376(3):235-242
pubmed: 27973993
Anal Chem. 2016 Dec 6;88(23):11476-11485
pubmed: 27779402
Neuropharmacology. 2016 Nov;110(Pt A):143-153
pubmed: 27449567
N Engl J Med. 2015 Jul 9;373(2):103-7
pubmed: 26154784
Biochem Pharmacol. 2019 Nov;169:113623
pubmed: 31472128
Sci Rep. 2017 Sep 5;7(1):10516
pubmed: 28874764